Newsroom
News from and about Adial as well as important reporting about the field of addiction.
Featured Story

Adial Announces Research Collaboration with UC San Diego to Advance Purnovate’s Adenosine Compounds
Under the collaboration agreement, Dr. Ernst and his team will initially test Purnovate’s adenosine compounds in non-clinical models of IBD with the goal of further validating the potential of Purnovate’s compounds as a treatment for IBD. Dr. Ernst stated, “Based on experience, I am keen to see whether these adenosine analogs can effectively address the historical challenges of solubility and biodistribution. My team looks forward to evaluating the compounds for their potential therapeutic benefit to patients suffering from inflammatory bowel disease and other inflammatory conditions.”
Learn MorePress Releases
Past NewsAdial Pharmaceuticals Provides Business Update and Reports First Quarter 2022 Financial Results
Continue ReadingAdial Pharmaceuticals Announces Research Collaboration with UC San Diego to Advance Purnovate’s Adenosine Compounds as Potential Treatments for Inflammatory Diseases & Disorders
Continue ReadingAdial Pharmaceuticals CEO to Participate in a Fireside Chat at the 2022 Virtual Growth Conference Presented by Maxim Group LLC and hosted by M-Vest on March 28th
Continue ReadingEvents
Past EventsYouTube Channel (AdialPharma)
Subscribe to ChannelAdial Overview 2020
Watch NowAdial Overview
Watch NowAbout the growing AUD market and Adial's targeted potential treatment
Watch NowNBC29: UVA Researchers & Adial looking into using Purnovate in Burn Wound Care
Watch NowCEO Bill Stilley talks about AD04 on CBS46 Atlanta
Watch NowNewsy Morning Rush with Bill Stilley discussing AUD & AD04
Watch NowIndustry News
Here are some of the latest noteworthy articles and studies related to Adial’s work.